1. Home
  2. ACB vs IMUX Comparison

ACB vs IMUX Comparison

Compare ACB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

HOLD

Current Price

$3.94

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$16.50

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACB
IMUX
Founded
2013
2016
Country
Canada
United States
Employees
N/A
66
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.3M
209.2M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
ACB
IMUX
Price
$3.94
$16.50
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
1.7M
144.9K
Earning Date
06-17-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.31
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.56
$0.51
52 Week High
$6.67
$17.43

Technical Indicators

Market Signals
Indicator
ACB
IMUX
Relative Strength Index (RSI) 73.07 61.52
Support Level $3.22 $0.75
Resistance Level $4.15 N/A
Average True Range (ATR) 0.18 1.09
MACD 0.08 0.17
Stochastic Oscillator 99.21 75.78

Price Performance

Historical Comparison
ACB
IMUX

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: